Stocktoria
REPLIGEN CORP RGEN
REPLIGEN CORP (RGEN) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $738.3M at a 6.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.51 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-03 | HSBC | Buy (main) |
| 2026-05-06 | JP Morgan | Overweight (main) |
| 2026-05-06 | Barclays | Overweight (main) |
| 2026-04-20 | Canaccord Genuity | Hold (main) |
| 2026-04-17 | Roth Capital | Buy (init) |
| 2026-04-14 | Barclays | Overweight (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.34 |
| Retained earnings / assets | 0.155 |
| EBIT / assets | 0.019 |
| Equity / liabilities | 2.497 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RGEN | REPLIGEN CORP | 6/9 | 5.48 | 169.6 | +16.4% |
| BCRX | BIOCRYST PHARMACEUTICALS INC | 6/9 | -2.63 | 9.6 | +94.1% |
| ADMA | ADMA BIOLOGICS, INC. | 5/9 | 8.8 | 13.8 | +19.6% |
| TARS | Tarsus Pharmaceuticals, Inc. | 4/9 | 2.84 | — | +146.7% |
| IMCR | Immunocore Holdings plc | 3/9 | 2.37 | — | +29% |
| KRYS | Krystal Biotech, Inc. | 5/9 | 16.61 | 53.6 | +33.9% |
| TWST | Twist Bioscience Corp | 3/9 | -2.72 | — | +20.3% |
About REPLIGEN CORP
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
FAQ
Is RGEN financially healthy?
REPLIGEN CORP's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does RGEN pay a dividend?
No, REPLIGEN CORP does not currently pay a dividend.
How profitable is RGEN?
In FY2025, REPLIGEN CORP had a net margin of 6.6% and a return on equity of 2.3%.
Is RGEN overvalued or undervalued?
REPLIGEN CORP trades at about 192.7× trailing earnings — above its 10-year norm (10-year range 49.1×–300.6×, median 154.1×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for RGEN?
The average Wall-Street price target for REPLIGEN CORP is $176.11, about 6.3% above the recent price, from 19 analysts (consensus: buy).
Is RGEN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on REPLIGEN CORP: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 169.6×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.